title: Toxicoses and efficacy associated with administration of mitoxantrone to cats with malignant tumors.
abstract: Eighty-seven cats with histologically confirmed malignant tumors were used in a prospective study to determine the toxicity of mitoxantrone, a dihydroxyquinone derivative of anthracene, which was administered at 21-day intervals at dosages ranging from 2.5 to 6.5 mg/m2 of body surface, IV. Eleven of these cats were treated concurrently with radiation but were evaluated separately. Each cat was evaluated for signs of toxicosis for 3 weeks after each dose was administered or until the cat developed progressive disease, or until the cat's quality of life diminished to an unacceptable level as determined by the owner or attending veterinarian. Although the primary purpose of this study was to determine a clinically useful dosage and to characterize the toxicoses associated with mitoxantrone administration, each cat was monitored for response to treatment. Forty-nine cats had been refractory to 1 or more treatment modalities prior to inclusion in this study. The most common signs of toxicosis after treatment with mitoxantrone were vomiting, anorexia, diarrhea, lethargy, sepsis secondary to myelosuppression, and seizures. Two cats died of complications that may have been attributed to mitoxantrone: 1 of cardiomyopathy and the other of pulmonary edema of an undetermined cause. Older cats were more likely to develop signs of toxicosis after the third or fourth mitoxantrone treatment than younger cats (P < or = 0.05). Cats with signs of toxicosis during the 21-day interval after administration of the first dose of mitoxantrone were significantly (P < or = 0.05) more likely to develop signs of toxicosis during the 21-day interval between the second and third doses of mitoxantrone.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins 80523.
authors.forename: G K
authors.initials: GK
authors.lastname: Ogilvie
authors.forename: A S
authors.initials: AS
authors.lastname: Moore
authors.forename: J E
authors.initials: JE
authors.lastname: Obradovich
authors.forename: R E
authors.initials: RE
authors.lastname: Elmslie
authors.forename: D M
authors.initials: DM
authors.lastname: Vail
authors.forename: R C
authors.initials: RC
authors.lastname: Straw
authors.forename: M D
authors.initials: MD
authors.lastname: Salmon
authors.forename: M K
authors.initials: MK
authors.lastname: Klein
authors.forename: S W
authors.initials: SW
authors.lastname: Atwater
authors.forename: P E
authors.initials: PE
authors.lastname: Ciekot
mesh_terms: D000818:Animals; D000855:Anorexia / Q000139:chemically induced / Q000662:veterinary; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy / Q000532:radiotherapy / Q000662:veterinary; D002371:Cat Diseases / Q000139:chemically induced / Q000188:drug therapy* / Q000532:radiotherapy; D002415:Cats; D017024:Chemotherapy, Adjuvant; D004305:Dose-Response Relationship, Drug; D005260:Female; D008297:Male; D008942:Mitoxantrone / Q000008:administration & dosage / Q000627:therapeutic use / Q000633:toxicity*; D009369:Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000662:veterinary*; D011446:Prospective Studies; D012074:Remission Induction; D014839:Vomiting / Q000139:chemically induced / Q000662:veterinary
chemical_list: D008942:Mitoxantrone